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Abstract 
Background: Perivascular adipose tissue (PVAT) surrounds most blood vessels and secretes 
numerous active substances, including adiponectin which produce a net anticontractile effect 
in healthy PVAT. AMP-activated protein kinase (AMPK) is a key mediator of cellular energy 
balance and may mediate the vascular effects of adiponectin. In this study we investigated the 
role of AMPK within PVAT in mediating the anticontractile effect of PVAT. 
 
Methods: Endothelium-denuded aortic rings from wild-type (Sv129) and α1AMPK knockout 
(KO) mice were mounted on a wire myograph. Dose-response curves to the AMPK-
independent vasodilator cromakalim were studied in vessels with and without PVAT and the 
effect of preincubation with conditioned media (CM) and adiponectin on relaxation also 
studied. The effect of AMPKα1 KO on the secretory profile of PVAT was assessed by 
ELISA. 
 
Results: Thoracic aortic PVAT from KO mice was morphologically indistinct from WT and 
primarily composed of brown adipose tissue. PVAT augmented relaxation to cromakalim in 
WT but not KO mice. Addition of WT PVAT augmented relaxation in KO aortic rings but 
KO PVAT had no effect in WT mice. PVAT from KO mice secreted significantly less 
adiponectin and addition of adiponectin to either KO or WT aortic rings without PVAT 
augmented relaxation to cromakalim. An adiponectin blocking peptide significantly 
attenuated relaxation in WT rings with PVAT but not in KO rings.  
 
Conclusion: This study demonstrates that AMPKα1 has a critical role in maintaining the 
anticontractile actions of PVAT; an effect independent of the endothelium but likely 
mediated through altered adiponectin secretion or sensitivity.  
 
Abbreviations: PVAT- perivascular adipose tissue; AMPK- AMP-activated protein kinase; 
WT- wild type; KO- knock-out; WAT- white adipose tissue; BAT- brown adipose tissue; 
CM- conditioned media; VSMCs- vascular smooth muscle cells; UCP-1- uncoupling protein-
1; ACC- Acetyl CoA carboxylase; ADRF- adventitia-derived relaxing factor; sGC- Soluble 
guanylyl cyclase. 
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1. Introduction 
Perivascular adipose tissue (PVAT) surrounds almost all blood vessels and is increasingly 
recognised as an important regulator of vascular tone. As an active endocrine organ the 
adipocytes and stromal cells within PVAT produce and secrete a range of adipokines, 
inflammatory cytokines, and other factors which can influence the tone of the underlying 
blood vessel  (Dubrovska et al., 2004; Malinowski et al., 2008; Weston et al., 2013). PVAT 
can release substances with vasodilatory activity such as adipocyte-derived relaxing factor 
(ADRF) (Galvez et al., 2006; Lohn et al., 2002; Verlohren et al., 2004), leptin (Vecchione et 
al., 2002), adiponectin (Chen et al., 2003; Fesus et al., 2007), angiotensin 1–7 (Ang 1-7) (Lee 
et al., 2009), hydrogen peroxide (Gao et al., 2007), nitric oxide (NO) (Gil-Ortega et al., 
2010) and hydrogen sulphide (H2S) (Fang et al., 2009) but also vasoconstrictor factors such 
as angiotensin II (Ang II) (Galvez-Prieto et al., 2008) and superoxide anions (Gao et al., 
2006). Consequently, a balance exists and much research effort has been channeled into 
discovering what causes the function of PVAT to change in disease states such as obesity and 
metabolic syndrome where PVAT become deleterious to blood vessel activity.  
PVAT is composed of brown adipocytes, white adipocytes or a mixture of both depending on 
the vascular bed (Cinti, 2011; Fitzgibbons et al., 2011; Gao, 2007). In healthy humans and 
experimental animals, PVAT has a net anticontractile effect (Greenstein et al., 2009; Lohn et 
al., 2002), but the precise mechanisms remain elusive. The anti-contractile effect is likely due 
to release of transmissible factors; a process that requires calcium but is not dependent on 
perivascular nerve activity (Dubrovska et al., 2004). In rat mesenteric vessels the 
anticontractile effect of PVAT is dependent on activation of delayed rectifier potassium 
channels (KV) on the vascular smooth muscle (Verlohren et al., 2004) while in rat aortic 
rings, Gao et al found that a PVAT-derived transmissible factor induced relaxation by: (1) an 
endothelium-dependent effect via NO release and subsequent KCa channel activation, and (2) 
an endothelium-independent mechanism involving H2O2 and subsequent activation of sGC 
(Gao et al., 2007). More recent work has identified adiponectin as an abundant adipokine 
with anticontractile activity. In mouse mesenteric vessels and rat aorta, adiponectin was 
found to relax vascular smooth muscle cells via Kv channel opening and membrane 
hyperpolarisation (Fesus et al., 2007). However, other studies using mouse mesenteric 
vessels found that adiponectin requires the presence of large conductance calcium-activated 
potassium channels (BKCa) in order to hyperpolarise VSMCs and exert an anticontractile 
effect (Lynch et al., 2013). Interestingly, a recent study by Weston’s group has shown that 
adiponectin-mediated hyperpolarisation was inhibited by a selective inhibitor of AMP-
activated protein kinase (AMPK) and that the effect of adiponectin was mimicked by the 
AMPK activator, A769662 (Weston et al., 2013). Activation of AMPK is proposed to trigger 
opening of myocyte BKCa channels and release of NO which accounts for the anticontractile 
effect of adiponectin. Indeed, in mice lacking the AMPKα2 catalytic subunit isoform, 
globular adiponectin failed to induce vascular relaxation (Meijer et al., 2013) suggesting that 
adiponectin requires AMPK to exert an anticontractile effect. 
Although AMPK is often described as a cellular energy gauge and modulator of cellular 
metabolism (Hardie et al., 2003), it also has important roles in maintaining vascular 
homeostasis (Ewart et al., 2011). It is expressed throughout the vessel wall and can respond 
to changes in cellular energy state (Evans et al., 2005; Fleming et al., 2005), hormonal 
changes (Cheng et al., 2007; Nagata et al., 2004), and drugs (Bilodeau-Goeseels et al., 2011; 
Ford et al., 2012; Levine et al., 2007) to regulate vascular tone. AMPK activation can induce 
vasodilation via phosphorylation and activation of endothelial NO synthase (eNOS) at Ser1177 
(Davis et al., 2006; Morrow et al., 2003) and Ser633 (Chen et al., 2009) to increase NO 
production and vascular relaxation (Davis et al., 2006; Morrow et al., 2003). AMPK can also 
induce endothelium-independent relaxation via reduced sensitivity of myosin light-chain 
kinase (MLCK) to intracellular calcium (Horman et al., 2008). Collectively, these findings 
suggest that AMPK activation can induce vasodilation but may also be involved in the 
vascular effects of PVAT. However, despite AMPKα1 being the dominant vascular isoform, 
nothing is known about its role in mediating the anticontractile effect of PVAT. 
The aim of this study was to investigate aortic PVAT function in a mouse with a global 
AMPKα1 isoform knockout. Furthermore, we wished to study whether lack of this AMPK 
isoform in the vascular wall affects the generation and vascular effects of adiponectin. 
  
2. Methods 
2.1. Animal model and artery preparation  
Mice used in this study were housed at the University of Glasgow and maintained on 12 hour 
cycles of light and dark and at ambient temperature. Wild type (Sv129- WT) mice were 
originally purchased from Harlan Laboratories (Oxon, UK). AMPKα1 knockout mice (KO) 
were kindly supplied by Benoit Viollet (Institut Cochin, Paris, France), the generation of 
which has been described previously (Jørgensen et al., 2004). In all experiments age-matched 
male and female WT and KO mice were used since pilot experiments showed no gender 
difference in vessel contractility and relaxation (data not shown). Procedures conformed to 
the Guide for the Care and Use of Laboratory Animals published by the US National 
Institutes of Health (NIH Publication No. 85-23, revised 1996) and Directive 2010/63/EU of 
the European Parliament. Mice were terminally anaesthetized via intraperitoneal injection of 
sodium pentobarbital (200mg ml-1) and the thoracic and abdominal aorta was removed to ice 
cold oxygenated (95% O2:5% CO2) Krebs’ solution. In some experiments, mesenteric and 
other fat depots were also removed for histological analysis. 
 
2.2. Histological analysis  
Thoracic aortae with intact PVAT were fixed overnight in 10% acetic zinc formalin, 
dehydrated and embedded in paraffin. Sections (5 µm) of aorta were cut on a rotary 
microtome and stained with haematoxylin and eosin. To compare the morphology of aortic 
PVAT to other fat depots, mesenteric PVAT, subscapular brown adipose tissue (BAT) and 
epididymal white adipose tissue (WAT) were also fixed, sectioned and stained with H&E. 
Immunohistochemistry was used to detect antigens of interest within the PVAT. Briefly, 
slides were deparaffinised and antigens were retrieved by heating in a microwave oven in 
Sodium Citrate buffer (10 mM Na citrate, 0.05% (v/v) Tween 20, pH 6.0) for 10 min. Slides 
were cooled at room temperature and endogenous peroxidase activity blocked by immersing 
in 3 % (v/v) H2O2 in methanol for 20 min. Non-specific antibody binding was blocked using 
2.5 % (v/v) normal horse serum (ImmPRESS Reagent Kit, Vector labs, USA) for 1 h at room 
temperature and primary antibodies were then added overnight at 4oC. Primary antibodies 
were diluted in 1 % (w/v) BSA in PBS and used at the following concentrations: anti-total 
AMPK 1:100 (Abcam #131512), anti-phospho-AMPK Thr172 1:100 (Cell Signalling 
Technology #2535), anti-UCP-1 1:500 (Abcam #10983). Blanks and negative controls were 
included in each staining run. Secondary antibodies were incubated for 1 h at room 
temperature (ImmPRESS anti-rabbit Ig antibodies; Vector Labs, USA for UCP-1 or 
Biotinylated anti-rabbit IgG antibody from Histostain-Plus bulk kit, Life technologies, UK 
for total and phosphor-AMPK). Antibody binding was visualised using DAB (3,3' 
diaminobenzidine) chromogenic substrate (Vector Laboratories) and haematoxylin counter 
stain. Sections were photographed using AxioVision microscope software (Zeiss, Germany). 
 
2.3. Small vessel wire myography 
The thoracic and, in some experiments the abdominal aorta was cut into 2mm rings. Some 
rings were cleaned of PVAT and others were left with the PVAT intact. In all cases the 
endothelium on the luminal surface was removed by gently rubbing the interior of the vessel 
with a piece of fine wire and removal confirmed by lack of (<10%) vasodilator response to 
10-6 M acetylcholine. Artery rings were mounted on two stainless steel pins in a four channel 
wire myograph (Danish Myo Technology), set to an optimum tension of 9.8 mN 
(Weingartner et al., 2015) and allowed to equilibrate for at least 30 min before use. Vessels 
were bathed in Krebs’ buffer of the following composition: 118 mM NaCl, 4.7 mM KCl, 1.2 
mM MgSO4, 25 mM NaHCO3, 1.03 mM KH2PO4, 11 mM glucose and 2.5 mM CaCl2 at 
37oC and gassed continuously with 95% O2 and 5% CO2. Reproducible responses
 were 
obtained to 40mM KCl and 30nM 9,11-Dideoxy-9α,11α-methanoepoxy prostaglandin F2α 
(U46619, Tocris) before commencing experiments. Cumulative concentration-response 
curves to the K+ channel opener cromakalim (1x10-9 to 1x10-6 M; Sigma-Aldrich, Poole, 
UK), added at 10 min intervals were constructed. Data were expressed as a percentage loss of 
U46619-induced tone. 
To produce conditioned media (CM), thoracic aortic PVAT from WT and KO mice was 
carefully dissected, weighed and incubated in warmed Krebs’ solution at 37 ˚C for 1 h. The 
conditioned medium was transferred to the recipient myograph chamber containing an aortic 
ring at baseline tension. The ring was then contracted and dose-response curves to 
cromakalim constructed as previously. In some experiments, PVAT from KO mice was 
added to WT aortic rings and vice-versa (termed a cross-over experiment). 
To study the role of adiponectin in the anticontractile effect of PVAT, two separate 
experiments were performed. Firstly, 5µg mL-1 of an adiponectin blocking peptide against 
adiponectin receptor 1 (AdipoR1; GeneTex, UK) was added to preconstricted aortic rings 
with and without PVAT. Secondly, globular adiponectin (1µg mL-1 diluted in 1% (w/v) 
bovine serum albumin (BSA); Enzo Life Sciences Ltd, UK) was added to arteries prior to 
contracting with U46619. In both cases, dose-response curves to cromakalim were then 
constructed in WT and KO aortic rings. 
 
2.4. Effect of cromakalim on AMPK activity in cultured cells 
Rat aortic smooth muscle cells from Wistar-Kyoto rats were provided Dr Augusto Montezano 
(University of Glasgow) and maintained in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% (v/v) FBS (Invitrogen, UK), 100 U ml-1 pencillin and 100 µg ml-1 
streptomycin. At passage 4 to 5 the cells were washed with PBS and incubated in serum-free 
medium for 2 hours. Cells were incubated with the AMPK-activating agent AICAR (10-2-10-
3M) or cromakalim (10-8-10-6M) for 45 minutes, the medium was removed, lysis buffer added 
(50 mM Tris pH7.4, 50 mM NaF, 1 mM Na4P2O7, 1 mM EGTA, 1mM EDTA, 1% (v/v) 
Triton X-100, 1 mM DTT and 1% cocktail of protease inhibitors with 2mM Na3VO4) and the 
cells collected by scraping. Lysates were placed on ice for 30 min, centrifuged at 8000 rpm 
for 10 min and supernatants collected and used for immunoblotting. 
 
2.5 Protein expression/immunoblotting 
The protein content of VSMC lysates (or in some experiments PVAT lysates or conditioned 
media samples) was determined using Coomassie Plus Protein Assay Reagent (Perbio, USA) 
against a BSA standard curve. Samples were run on NuPAGE Novex 4-12 % Bis-Tris mini 
gels (Life Technologies), transferred to nitrocellulose membranes and incubated with specific 
rabbit anti-total AMPKα (Cell Signalling Technology #2603), anti-AMPKα1(Abcam 
#ab110036), anti-AMPKα2 (Generous gift from Prof. Grahame Hardie, University of 
Dundee, UK), anti-phospho-Thr172 AMPK (Cell Signalling Technology #2535) and anti-
phospho-Ser79 ACC (Cell Signalling Technology #3661) antibodies. All primary antibodies 
were diluted 1:1000 in 50% (v/v) TBS, 50% (v/v) Odyssey®-Block (LI-COR, USA). 
Immunolabelled proteins were visualized using infrared dye-labelled secondary antibodies 
and an Odyssey Sa Infrared Imaging System (LI-COR, USA) and expression normalised to 
anti-GAPDH antibody immunoreactivity (Cell Signaling Technology). 
 
2.6 Array and adiponectin ELISA 
Adipokine expression profiling was performed using an Adipokine proteome profiler, (R&D 
systems, UK) following the protocol provided by the manufacturer. Briefly, 1 ml of pooled 
samples of homogenised PVAT or conditioned medium from WT and KO mice were added 
to the array membranes and incubated at 4°C overnight. After washing, membranes were 
incubated with 2 ml of horseradish peroxidase–conjugated streptavidin at room temperature 
for 30 min and the presence of adipokines detected by chemiluminescence. The resultant film 
images were scanned with a densitometer and converted to densitometric units using Quantity 
One software (Bio-Rad Laboratories, Hercules, CA, USA). Data were normalized against an 
internal control as recommended by the manufacturer. 
To study adiponectin release by PVAT, a mouse adiponectin/Acrp30 Quantikine ELISA Kit 
(MRP300, R&D systems, Minneapolis, MN) was used. Samples of homogenised PVAT and 
conditioned media from WT and KO mice were prepared and protein concentration 
determined. Adiponectin was detected as a colourimetric reaction measuring absorbance of 
the ELISA plate at 450 nm with wavelength correction using a FLUOstar OPTIMA 
microplate reader (BMG Labtech, Germany). The mean absorbance from each sample was 
measured in duplicate and the adiponectin concentration was determined by comparison with 
the standard curve.  
2.7. Statistical analysis 
All results are expressed as mean ± standard error of the mean (SEM). The n number stated in 
all cases represents the number of mice from which tissue was obtained. Data were analysed 
with GraphPad Prism 5.0 software. Myography data was analysed using 2-way ANOVA. 
When comparing three or more data groups, two-way ANOVA followed by Bonferroni post-
hoc tests were used. When comparing two or more data groups a Newman–Keuls post hoc 
test was used. In all cases, a p value of less than 0.05 was considered statistically significant. 
  
3. Results 
3.1. PVAT morphology and AMPK expression 
In haematoxylin and eosin stained sections, there were no gross differences in PVAT or other 
fat depots between WT and AMPKα1 KO mice (Figure 1). In both strains, thoracic PVAT 
had the appearance of BAT with round nuclei, and small, multilocular lipid droplets, whereas 
mesenteric PVAT was very similar to WAT, with large single lipid vacuoles and marginal 
nuclei. Abdominal PVAT showed features of both BAT and WAT. Immunohistochemical 
staining for the brown adipose tissue marker UCP-1 was similar in WT and KO aortic PVAT 
with very low staining in mesenteric fat and some staining present in abdominal aortic PVAT 
(supplementary Figure S1, S2). 
AMPKα and phospho-AMPKα (pAMPKα) were detected immunohistochemically in thoracic 
PVAT and there was a marked reduction in both total and phospho-AMPKα Thr172 in KO 
mice (data not shown). Western blotting was used to quantify AMPK levels in homogenised 
PVAT. As expected, there was a marked reduction in total levels of AMPKα, phospho-
AMPKα Thr172 and phospho-ACC Ser79 (pACC). When expressed relative to total AMPKα, 
there was a modest reduction in the level of phosphorylated AMPKα in KO mice in 
comparison with wild type (Figure 2). There was no substantial difference in AMPKα2 
immunoreactivity between genotypes. 
 
3.2. Anticontractile effect of PVAT and importance of AMPK 
The presence or absence of the vascular endothelium did not affect the contractile response to 
U46619 in WT or KO aortae (data not shown). In aortic rings without PVAT there was no 
significant difference in contraction between WT and KO mice (Figure 3A). In rings 
containing PVAT, contraction to U46619 was significantly reduced in the WT but not the KO 
mice (Figure 3A), indicating an anticontractile effect of the PVAT which was lost when the 
PVAT is deficient in AMPKα1. 
The presence of PVAT significantly increased the relaxation to cromakalim in thoracic aortic 
rings from WT mice but this effect was completely absent in AMPKα1 KO mice (Figure 3B, 
C). To check that the effect of PVAT was not specific to the thoracic aorta, the experiment 
was repeated in abdominal aorta and similar results were found: WT vessels with intact 
PVAT, maximum relaxation (Emax) to cromakalim was 53.3 ± 5.2% with PVAT, and 24.5 ± 
5.7% without PVAT (n = 6; p<0.05 vs. PVAT+) while in KO mice PVAT had no effect on 
Emax to cromakalim (22.8 ± 5.8% vs. 17.4 ± 4.1%, n = 6; p=ns). 
In WT mice, PVAT which had been dissected free of the artery and added back into the organ 
bath was able to augment relaxation to cromakalim equally as well as when the PVAT was in 
contact with the artery (Emax 54.5± 8.3% vs. 49.9 ± 6.7%; n=5; p=ns), suggesting the PVAT 
releases a transmissible factor which is responsible for increased relaxation. In contrast, 
addition of PVAT from KO mice to an aortic ring from WT mice did not augment relaxation 
to cromakalim (Figure 4A, B) whereas adding WT PVAT to a KO aortic ring did augment 
relaxation. Furthermore, addition of conditioned media (CM) produced by WT PVAT was 
able to augment cromakalim-induced relaxation in WT aortic rings while CM produced by 
KO PVAT was unable to augment relaxation (Figure 4C, D). Wild type CM also significantly 
attenuated contraction to U46619 in WT rings without PVAT (1.19 ± 0.1g vs. 0.86 ± 0.1 g 
with addition of CM; n=12; p<0.05). In contrast, KO conditioned media showed a non-
significant trend toward increased contraction (2.33 ± 1.3g vs. 2.80 ± 1.4g with addition of 
CM; n =12). Transfer of WT PVAT into KO vessels without PVAT and CM experiments 
indicates that the deficiency in the KO mouse is likely to be at least partly related to 
differences in release of adipokines by the PVAT. 
 
3.3. Cromakalim does not activate AMPK in vascular smooth muscle cells 
To rule out the possibility that vasodilation to cromakalim is altered in KO mice because 
cromakalim activates AMPK, cultured rat VSMCs were treated with a range of 
concentrations of cromakalim and the AMPK activator AICAR as a positive control. 
Cromakalim did not increase phosphorylation of AMPK in the vascular smooth muscle and 
had no effect on the phosphorylation of the downstream substrate ACC. AICAR caused an 
increase in AMPK activity (supplementary Figure S3) at a concentration of 10-3 M. 
 
3.4 Adipocytokine profile and effect of AMPK KO 
Adipocytokine profiling of PVAT-derived conditioned media showed a striking reduction in 
the amount of adiponectin released by PVAT from AMPKα1 KO mice (n=2; data not 
shown). Further quantification of this difference by ELISA in n=5 samples of conditioned 
medium from KO and WT mice revealed a significant reduction in the quantity of 
adiponectin released by KO PVAT (Figure 5). 
 3.5 Effect on adiponectin on vessel function 
Addition of globular adiponectin to WT aortic rings without PVAT significantly increased 
relaxation to cromakalim (Figure 6A). Interestingly, globular adiponectin enhanced the 
relaxation to cromakalim in KO vessels both with and without PVAT (Figure 6B, C). 
Blocking adiponectin receptors in WT aortic rings with intact PVAT significantly attenuated 
relaxation to cromakalim (Figure 7A) while in KO arteries with intact PVAT, the blocking 
peptide had no effect (Figure 7B). Taken together, these results suggest that KO PVAT 
releases less adiponectin but that the medial smooth muscle cells are still able to respond to 
exogenously added adiponectin. 
  
4. Discussion 
The main findings of this study are that the anticontractile effect of aortic PVAT is lost in 
mice which lack AMPKα1 and this is due to reduced generation of a transmissible factor, 
likely adiponectin, by the PVAT. The results also demonstrate that the lack of an 
anticontractile effect in the KO mouse is not due to alterations in PVAT morphology or the 
ratio of BAT to WAT or to the absence of AMPK expression in the medial smooth muscle 
cells of the aorta. Since incubation with globular adiponectin augmented relaxation to 
cromakalim in KO arteries without PVAT, it is also unlikely to be due to a reduced 
sensitivity of the medial VSMCs to adiponectin. In summary, AMPKα1 plays a critical role 
in maintaining the anticontractile actions of PVAT; an effect independent of the endothelium 
but likely mediated through altered adiponectin secretion. 
Morphological studies revealed no difference in PVAT from WT and KO mice. Thoracic 
aorta was similar in appearance to depots of BAT from the subscapsular region while 
abdominal aorta showed a mixture of WAT and BAT. This is in agreement with previous 
studies using Sv129 mice (Cinti, 2011; Frontini et al., 2010) and also from other mouse 
strains (Cannon et al., 2004; Fitzgibbons et al., 2011; Padilla et al., 2013). It has been 
speculated that differences in PVAT phenotype could contribute to disease susceptibility of 
certain regions of the arterial tree (Greif et al., 2009; Jeong et al., 2007), possibly through 
release of proinflammatory cytokines (Chatterjee et al., 2009; Payne et al., 2010; Zhao et al., 
2003). Certainly, in animal models of obesity, there is evidence for a detrimental effect of 
PVAT on vascular function in aortic (Ma et al., 2010) and mesenteric arteries (Ketonen et al., 
2010; Marchesi et al., 2009) and in animals fed a high fat diet, there was reduced 
phosphorylation of AMPK in thoracic aortic PVAT, an increased adipocyte size and 
increased intimal thickness (Ma et al., 2010). Taken together, these studies suggest that 
AMPK in the PVAT is likely to be protective and this agrees with the data presented here 
showing that the anticontractile effect of thoracic (and abdominal) PVAT is lost in mice 
lacking AMPKα1. We also demonstrated that in the KO mouse there was reduced 
phosphorylated and total AMPK in PVAT as well as reduced phosphorylation of the 
downstream kinase ACC. There was also no obvious compensatory upregulation in AMPKα2 
isoforms. The dramatic effect of α1 KO on PVAT function is in agreement with other studies 
showing that in adipose tissue the catalytic α1 subunit is the major isoform expressed and is 
also responsible for the major part of AMPK activity (Daval et al., 2005; Lihn et al., 2004). 
The lack of AMPKα1 caused the PVAT to lose its anticontractile effect and its presence no 
longer augmented relaxation to cromakalim. To rule out any differences being due to 
cromakalim acting through AMPK, we added cromakalim to cultured vascular smooth 
muscle cells and found it had no effect on AMPK expression or phosphorylation. Many other 
studies have found an anticontractile effect of PVAT in a variety of vascular beds (Gao et al., 
2005b; Greenstein et al., 2009) and in vessels contracted with several different 
vasoconstrictor agents including phenylephrine, 5-HT, angiotensin II and U 46619 (Gao et 
al., 2005a; Lohn et al., 2002; Verlohren et al., 2004). The mechanism has been proposed as 
release of transferable relaxation factor(s), termed adventitia-derived relaxation factor 
(ADRF). The nature of ADRF is largely unknown. However, it has been shown to act in part 
via activation of K+ channels and tyrosine kinase and independent of NO and sympathetic 
nerve stimulation (Lohn et al., 2002). Our data agree with this in that transfer of CM from 
WT mice augmented relaxation of aortic rings with PVAT. In addition, it was not necessary 
for the PVAT to be in contact with the vessel to exert an anticontractile effect. In our protocol 
we added the CM prior to contraction of the vessel ring with U46619 and found that WT but 
not KO CM attenuated aortic contraction. This strongly suggests a transmissible factor is 
responsible for attenuating contraction and augmenting relaxation which is produced by 
aortic PVAT and in the KO mice this factor is reduced or absent. The deficiency in the KO 
mouse is unlikely to be due to a lack of AMPK in the medial smooth muscle cells since in 
cross over studies WT PVAT was able to augment the relaxation response to cromakalim in 
KO vessels. However, it is worth noting that relaxations to cromakalim tended to be lower in 
KO rings without PVAT and while exogenously added WT PVAT or WT conditioned media 
significantly augmented relaxation to cromakalim in KO aortic rings, it still did not reach 
levels seen in WT vessels with intact PVAT. This suggests there may be some deficit in 
function of the VSMCs in the KO mice and future experiments should use an adipocyte-
specific AMPK KO to address this. 
The release of the vasorelaxing factors (ADRF) has been reported to be dependent on calcium 
(Ca2+) and is regulated by intracellular signalling pathways involving tyrosine kinase and 
protein kinase A and not to be dependent on perivascular nerve endings (Dubrovska et al., 
2004). There are very few studies where the role of AMPK in release of ADRFs has been 
investigated. A study by Lihn et al indicated that the AMPK activator AICAR stimulated 
adipose tissue AMPKα1 activity and adiponectin gene expression and reduced the release of 
TNF-α and IL-6 (Lihn et al., 2004). These cytokines have been shown to have inhibitory 
effects on adiponectin gene expression and release (Fasshauer et al., 2002; Lihn et al., 2003; 
Maeda et al., 2002), meaning that activity of AMPK in the PVAT could regulate adiponectin 
expression (Lihn et al., 2004). Similarly, the PPARγ agonist troglitazone which also activates 
AMPK has a positive effect on adiponectin expression in mature adipocytes (Phillips et al., 
2003). However, other studies using cultured 3T3-L1 adipocytes found that prolonged 
exposure to AMPK activating agents actually causes a significant reduction in adiponectin 
protein content of the adipocytes (Huypens et al., 2005). 
To clarify how AMPKα1 KO affects the secretion of adipocytokines by aortic PVAT, we 
performed an array and the most striking difference was a reduction in adiponectin in KO 
PVAT and CM. Quantitative studies using ELISA further confirmed a significant reduction 
in adiponectin in KO CM. Since adiponectin is a vasodilator (Fesus et al., 2007), it could 
account for the lack of an anticontractile effect in KO PVAT. Indeed, in WT mice the 
anticontractile effect of PVAT was abolished using a adiponectin receptor blocking peptide, 
an effect demonstrated previously in human gluteal arteries (Fesus et al., 2007) and mouse 
mesenteric arteries (Lynch et al., 2013). We also demonstrated the ability of both KO and 
WT aortic rings without PVAT to increase relaxation to cromakalim when pretreated with 
globular adiponectin. Since all rings were denuded of endothelium, it suggests the ability of 
adiponectin having direct access to vascular smooth muscle cells (Weston et al., 2013). The 
adiponectin enhanced vascular relaxation was also observed in in KO vessels with intact 
PVAT, indicating that there was no perfusion barrier between PVAT and vascular smooth 
muscle layer. Additionally, vascular relaxation was seen in both wild type and AMPKα1 
knockout vessels suggesting that adiponectin can act directly on vascular smooth muscle cells 
and that the AMPKα1 isoform is not involved. 
Only one vasodilator was used in the current study; the KATP channel activator cromakalim. 
KATP channels in VSMCs may be involved in mediating the anticontractile effects of PVAT 
since a previous study showed an inhibitory effect of glibenclamide (Lohn et al., 2002). KATP 
channels appear to regulate basal tone in a number of vascular bed such as coronary 
circulation (Samaha et al., 1992) and mesenteric vessels (Nelson et al., 1995) and inhibition 
of this channel by glibenclamide has been found to attenuate coronary and cerebral 
autoregulation (Hong et al., 1994; Narishige et al., 1993). In our study, since PVAT enhanced 
the relaxation induced by cromakalim, adiponectin released by the PVAT may act in part 
through modulating KATP channels. However, the role and the mechanism of activation need 
to be further investigated.  
In conclusion, we have shown that PVAT has a profound anticontractile effect on mouse 
aortic rings. The effect may be due to release of adiponectin by the PVAT and this release is 
regulated by the activity of AMPKα1. In mouse aortic rings, adiponectin augments relaxation 
to cromakalim in an endothelium-independent manner although other effects of adiponectin 
on the endothelium cannot be ruled out. Indeed, although aortic rings in this study were 
mechanically denuded, endothelial cells in vessels within the vasa vasorum will remain and 
adiponectin may have effects here. Clinically, there is evidence that PVAT becomes 
dysfunctional in obese humans and plasma adiponectin is reduced (Aghamohammadzadeh et 
al., 2015). Alterations in AMPK activity in the PVAT may be behind this effect. 
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Figure & Legends: 
 
Figure 1: Representative photomicrographs showing the morphology of fat depots in WT and 
AMPKα1 KO mice. Panels A & B- subscapular brown adipose tissue (BAT) Panels C & D- 
epididymal white adipose tissue (WAT), Panels E & F- thoracic perivascular adipose tissue 
(PVAT), Panels G & H- abdominal PVAT and Panels I & J- mesenteric PVAT. Aortic PVAT 
had the morphology of BAT. AO= aorta, MA= mesenteric artery, scale bar = 20µm). 
 
Figure 2: Western blotting showing expression of AMPKα isoforms and the downstream 
kinase ACC expression in PVAT from WT (right lanes) and KO mice (left lanes). KO mouse 
PVAT showed a reduction in expression of AMPKα1 and total AMPKα with no change in 
AMPKα2. KO PVAT also had significantly reduced phosphoAMPK and ACC. *p<0.05 WT 
PVAT; n=5. 
 
Figure 3: A- U46619-induced contraction was not significantly different in WT and KO 
thoracic aorta rings in the absence of PVAT. In vessels with attached PVAT, there was a 
significant reduction in contraction in WT but not KO aortic rings. (n=7; *p<0.05 and 
***p<0.001). B- The presence of PVAT significantly augmented the relaxation to 
chromakalim in WT aortic rings (n=7; ***p<0.001 vs. PVAT(-)). C- In aortic rings from 
AMPKα1 KO mice, the presence of PVAT had no effect on relaxation to cromakalim (n=7). 
 
Figure 4: In cross-over experiments using aortic rings without PVAT, addition of WT PVAT 
enhanced cromakalim induced relaxation in KO aortic rings (A). However, addition of KO 
PVAT to WT aortic rings (B) did not significantly alter the relaxation to cromakalim (n=6; 
***p<0.001 vs. PVAT(-). Conditioned media from WT aortic PVAT significantly enhanced 
relaxation to cromakalim (C) while KO conditioned media had no effect on relaxation to 
cromakalim (D). (n=6; ***p<0.001 vs. PVAT(-). 
 
 
Figure 5: Adiponectin concentration of conditioned media from WT and KO mice determined 
using an ELISA kit. WT PVAT released significantly more adiponectin than KO PVAT 
(**p˂0.01; n =5). 
 
Figure 6: A- Incubation of WT aortic rings without PVAT with 1µg mL-1 globular 
adiponectin significantly augmented relaxation to cromakalim. In KO mice, incubation with 
globular adiponectin significantly enhanced relaxation to cromakalim in aortic rings without 
PVAT (B) and also in rings where the PVAT was intact (C). (n =5, ***p < 0.001 vs. PVAT(-
)).  
 
Figure 7: In aortic rings with intact PVAT, addition of 5µg mL-1 of the adiponectin receptor 1 
(AdipoR1) blocking peptide significantly attenuated relaxation to cromakalim in WT mice 
(A) but had no effect in rings from KO mice (B). (n =6, ***p < 0.001 vs PVAT(+)).  
 
  
Supplementary Figures 
 
Figure S1: Brown adipose tissue marker (UCP-1) present in different depots of adipose tissue 
from both wild type and AMPKα1 knockout mice. Representative histological sections of 
brown adipose tissue (BAT) (A&B), white adipose tissue (WAT)(C&D), thoracic PVAT 
(E&F), abdominal PVAT (G&H) and mesenteric PVAT (I&J) stained with anti UCP-1 and 
counterstained with haematoxylin. Positive immunoreactivity for UCP-1 is indicated by 
brown colour. (AO= aorta, MA= mesenteric artery, scale bar 20 μm, magnification x20) 
 
Figure S2: Brown adipose tissue marker (UCP-1) expression in different PVAT depots. UCP-
1 expression was divided by GAPDH to adjust for protein loading. Western blots were 
performed in BAT (brown adipose tissue); WAT (white adipose tissue); TA (thoracic artery 
PVAT); AA (abdominal aorta PVAT); MES (mesenteric artery PVAT) from WT and KO 
homogenates. Blot shown are representative n=3 for all groups. 
 
Figure S3: AMPK expression and activity in cultured rat aortic vascular smooth muscle cells 
(VSMCs). VSMCs samples were treated with AICAR and cromakalim, lysed and 
immunoblotting was performed. Graphs are expressed as the fold-change of the 
phosphorylated form of each enzyme divided by the total AMPKα (B) or total ACC (C) to 
measure the activation of the enzyme. Blots shown are representative; n=3 for all groups. 
 
 










